| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","company":"Sagimet Biosciences Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","article_chars":3617,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_17bc3b6f986962a3","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:30:28.395513+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"tm261563-1_nonfiling - none - 7.2031728s","final_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt","source_event_id":"evt_61c886d9195a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"48d323ef90d8febb","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-21","2026-04-22","2029","2027","2028","December 2020"],"entities":[{"asset_class":"equity","name":"Sagimet Biosciences Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"filing","name":"Form DEF 14A","relevance":"high","symbol":"","type":"filing_form"},{"asset_class":"equity","name":"Jennifer Jarrett","relevance":"high","symbol":"","type":"director_nominee"},{"asset_class":"equity","name":"Anne Phillips, M.D.","relevance":"high","symbol":"","type":"director_nominee"},{"asset_class":"equity","name":"David Happel","relevance":"high","symbol":"","type":"director_nominee"},{"asset_class":"equity","name":"George Kemble, Ph.D.","relevance":"high","symbol":"","type":"director_nominee"},{"asset_class":"equity","name":"Timothy P. Walbert","relevance":"medium","symbol":"","type":"director"},{"asset_class":"equity","name":"Paul Hoelscher","relevance":"medium","symbol":"","type":"director"},{"asset_class":"equity","name":"Elizabeth Grammer, Esq.","relevance":"medium","symbol":"","type":"director"},{"asset_class":"equity","name":"Beth Seidenberg, M.D.","relevance":"medium","symbol":"","type":"director"},{"asset_class":"equity","name":"Nominating and Corporate Governance Committee","relevance":"medium","symbol":"","type":"committee"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal beyond the fact that this DEF 14A was filed.","The filing\u2019s full contents (e.g., executive compensation, audit matters, proposals) are not included in the provided text excerpt.","The specific Annual Meeting date is not stated in the provided excerpt.","No stock ticker symbol is provided in the text excerpt."],"key_facts":["The company\u2019s board consists of eight directors divided into three classes with staggered three-year terms.","Jennifer Jarrett, Anne Phillips, M.D., David Happel, and George Kemble, Ph.D. (Class III directors) were nominated for election at the Annual Meeting for three-year terms expiring at the 2029 Annual Meeting.","The filing states that if a nominee is unable to serve, the Nominating and Corporate Governance Committee will recommend a replacement nominee and the Board may designate the replacement to stand for election.","The Class I directors are Timothy P. Walbert and Paul Hoelscher, with terms expiring at the 2027 annual meeting.","The Class II directors are Elizabeth Grammer, Esq. and Beth Seidenberg, M.D., with terms expiring at the 2028 annual meeting.","The Class III directors are Jennifer Jarrett, Anne Phillips, M.D., David Happel, and George Kemble, Ph.D., with terms expiring at the Annual Meeting.","Dr. Seidenberg and Dr. Kemble were initially elected pursuant to an Amended and Restated Voting Agreement entered into in December 2020 with certain investors, which terminated upon closing of the IPO.","The filing lists general criteria for board membership, including relevant experience, proven achievement and competence, sound business judgment, understanding of fiduciary responsibilities, and willingness/ability to devote sufficient time."],"numeric_claims":[{"label":"board_size","value":"8 directors"},{"label":"board_classes","value":"3 classes"},{"label":"term_length_years","value":"3-year terms"}],"primary_claim":"Sagimet Biosciences Inc. filed Form DEF 14A and nominated Class III directors (Jennifer Jarrett, Anne Phillips, M.D., David Happel, and George Kemble, Ph.D.) for election to three-year terms expiring at the 2029 Annual Meeting.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Sagimet Biosciences Inc. filed its DEF 14A proxy statement. The filing describes the company\u2019s three-class, staggered board structure and nominates certain Class III directors for election to terms expiring in 2029.","topics":["SEC filing","proxy statement","board of directors","director nominations","corporate governance","staggered board terms"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Sagimet Biosciences Inc. \u00b7 Filed 20260421","ticker":"SGMT","tickers":["SGMT"],"title":"SGMT filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-046006.txt"}... |